Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Yum China Holdings Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288.06 (market cap $39.89B), while Yum China Holdings Inc trades at $43.91 (market cap $14.80B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.7× Yum China Holdings Inc's market cap, and Yum China Holdings Inc pays a 2.7% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | YUMC | |
|---|---|---|
Market Cap | $39.89B | $14.80B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $57.95 |
52-Week Low | $278.09 | $40.18 |
Enterprise Value | $38.15B | $15.69B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $288.06, down 3.58% today, with a bullish technical signal supported by oscillators and strong institutional sentiment. The company reported robust revenue growth to $3.71B in 2025, turning profitable with net income of $313.75M, and shows a positive earnings beat trend. Recent news highlights pipeline advancements and strategic AI partnerships aimed at accelerating drug discovery.
Outlook remains positive with a consensus price target of $414.40, implying 44% upside, driven by pipeline diversification and market expansion. Key risks include clinical trial outcomes and dependence on key drug Amvuttra. Wall Street maintains strong buy consensus (75% buy ratings) amid expectations for sustained growth and potential S&P 500 inclusion.
YUMC trades at $43.9, up 2.05% today, with a bullish technical signal and strong analyst support. Recent earnings beats and the acquisition of Pizza Hut in mainland China highlight growth momentum. Revenue reached $11.80B in 2025, with net income of $929M, though cash flow trends show net outflows. The stock's P/E of 16.48 and ROE of 16.87% reflect solid fundamentals amid expansion efforts.
The outlook is positive, driven by brand expansion and consistent profitability, but risks include competitive pressures in China and cash flow volatility. With 73.68% of analysts rating it Buy, the stock offers value, though investors should monitor execution on the Pizza Hut integration and macroeconomic conditions affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
